Oncocyte [OCX] vs Thermo Fisher [TMO] Detailed Stock Comparison

Oncocyte Corporation

NASDAQ
Loading...

Thermo Fisher Scientific Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Oncocyte Corporation wins in 5 metrics, Thermo Fisher Scientific Inc. wins in 11 metrics, with 0 ties. Thermo Fisher Scientific Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Oncocyte Corporation Thermo Fisher Scientific Inc. Better
P/E Ratio (TTM) -0.81 25.84 Thermo Fisher Scientific Inc.
Price-to-Book Ratio 109.66 3.31 Thermo Fisher Scientific Inc.
Debt-to-Equity Ratio 3.07 82.91 Oncocyte Corporation
PEG Ratio 0.05 2.29 Oncocyte Corporation
EV/EBITDA -2.86 19.02 Thermo Fisher Scientific Inc.
Profit Margin (TTM) 39.34% 15.15% Oncocyte Corporation
Operating Margin (TTM) -3,220.57% 17.89% Thermo Fisher Scientific Inc.
EBITDA Margin (TTM) N/A 17.89% N/A
Return on Equity 496.38% 13.52% Oncocyte Corporation
Return on Assets (TTM) -173.67% 5.00% Thermo Fisher Scientific Inc.
Free Cash Flow (TTM) $-21.23M $6.29B Thermo Fisher Scientific Inc.
Dividend Yield N/A 0.38% N/A
1-Year Return 87.05% 22.27% Oncocyte Corporation
Price-to-Sales Ratio (TTM) 34.89 3.86 Thermo Fisher Scientific Inc.
Enterprise Value $60.65M $214.76B Thermo Fisher Scientific Inc.
EV/Revenue Ratio 32.24 4.75 Thermo Fisher Scientific Inc.
Gross Profit Margin (TTM) 67.57% N/A N/A
Revenue per Share (TTM) $0 $120 Thermo Fisher Scientific Inc.
Earnings per Share (Diluted) $-4.66 $18.18 Thermo Fisher Scientific Inc.
Beta (Stock Volatility) N/A 0.97 N/A
Short % of Float N/A 1.22% N/A

Oncocyte Corporation vs Thermo Fisher Scientific Inc. Stock Performance Analysis

Loading Price Chart...

OCX
TMO

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Oncocyte Corporation1.34%-5.93%15.30%10.64%12.92%-15.78%
Thermo Fisher Scientific Inc.-1.69%3.89%2.45%-6.72%-18.35%-20.01%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Oncocyte Corporation87.05%41.14%-93.86%-92.52%-95.03%-95.03%
Thermo Fisher Scientific Inc.22.27%-5.31%9.75%222.18%684.25%1,233.99%

Performance & Financial Health Analysis: Oncocyte Corporation vs Thermo Fisher Scientific Inc.

MetricOCXTMO
Market Information
Market Cap i$65.62M$174.55B
Market Cap CategoryMicro capLarge cap
10 Day Avg. Volume i363,8282,356,220
90 Day Avg. Volume i186,7652,071,517
Last Close$6.03$473.95
52 Week Range$2.33 - $8.51$385.46 - $643.99
% from 52W High-29.14%-26.40%
All-Time High$204.80 (Jan 04, 2016)$672.34 (Dec 27, 2021)
% from All-Time High-97.06%-29.51%
Growth Metrics
Quarterly Revenue Growth-0.76%0.06%
Quarterly Earnings GrowthN/A0.10%
Financial Health
Profit Margin (TTM) i0.39%0.15%
Operating Margin (TTM) i-32.21%0.18%
Return on Equity (TTM) i4.96%0.14%
Debt to Equity (MRQ) i3.0782.91
Cash & Liquidity
Book Value per Share (MRQ)$0.03$141.96
Cash per Share (MRQ)N/A$8.75
Operating Cash Flow (TTM) i$-63,291,000$8.29B
Levered Free Cash Flow (TTM) i$1.69M$5.51B
Dividends
Last 12-Month Dividend Yield iN/A0.38%
Last 12-Month Dividend iN/A$1.76

Valuation & Enterprise Metrics Analysis: Oncocyte Corporation vs Thermo Fisher Scientific Inc.

MetricOCX (Apr 08, 2026)TMO (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-0.8125.84
Forward P/E i-1.8517.16
PEG Ratio i0.052.29
Price to Sales (TTM) i34.893.86
Price to Book (MRQ) i109.663.31
Market Capitalization
Market Capitalization i$65.62M$174.55B
Enterprise Value i$60.65M$214.76B
Enterprise Value Metrics
Enterprise to Revenue i32.244.75
Enterprise to EBITDA i-2.8619.02
Risk & Other Metrics
Beta iN/A0.97
Book Value per Share (MRQ) i$0.03$141.96

Financial Statements Comparison: Oncocyte Corporation vs Thermo Fisher Scientific Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricOCX (2024)TMO (2025)
Revenue/Sales i1.88M44.56B
Cost of Goods Sold i1.14M26.32B
COGS % of Revenue i60.7%59.1%
Gross Profit i740,00018.24B
Gross Margin i39.3%40.9%
Research & Development i9.84M1.40B
Operating Income (EBIT) i-23.25M8.11B
Operating Margin i-1,235.9%18.2%
EBITDA i-21.22M11.86B
EBITDA Margin i-1,128.2%26.6%
Pre-Tax Income i-60.66M7.31B
Pre-Tax Income % of Revenue i-3,225.0%16.4%
Income Tax iN/A547.00M
Income Tax % of Revenue i0.0%1.2%
Net Income (Profit) i-60.66M6.72B
Profit Margin i-3,225.0%15.1%

Balance Sheet & Liquidity Metrics

MetricOCX (2024)TMO (2025)
Cash & Equivalents i8.64M9.85B
Total Current Assets i11.76M28.71B
Total Current Assets % of Revenue i625.1%64.4%
Total Current Liabilities i7.28M15.19B
Total Current Liabilities % of Revenue i386.8%34.1%
Long-Term Debt i2.37M35.85B
Long-Term Debt % of Revenue i125.9%80.5%
Total Shareholders Equity i-12.27M53.54B
Retained Earnings i-350.54M59.16B
Retained Earnings % of Revenue i-18,635.8%132.8%
Property, Plant & Equipment i5.32M0

Cash Flow Statement Comparison

MetricOCX (2024)TMO (2025)
Operating Cash Flow i-63.29M7.82B
Operating Cash Flow % of Revenue i-3,364.8%17.5%
Capital Expenditures i-512,000-1.48B
Free Cash Flow i-21.23M6.29B
FCF Margin i-1,128.6%14.1%
Debt Repayment i-201,000-3.51B
Common Stock Repurchase i-5.39M-3.00B

Short Interest & Institutional Ownership Analysis

MetricOCXTMO
Shares Short iN/A4.54M
Short Ratio iN/A2.38
Short % of Float iN/A1.22%
Shares Outstanding i28.60M371.62M
Float Shares iN/A371.07M
% Held by Insiders iN/A0.17%
% Held by Institutions iN/A95.23%
% Held by Public iN/A4.60%

Dividend Analysis & Yield Comparison: Oncocyte Corporation vs Thermo Fisher Scientific Inc.

MetricOCXTMO
Last 12-Month Dividend iN/A$1.76
Last 12-Month Dividend Yield iN/A0.38%
3-Year Avg Annual Dividend iN/A$1.60
3-Year Avg Dividend Yield iN/A0.08%
3-Year Total Dividends iN/A$4.80
Ex-Dividend DateN/AMar 13, 2026